NTRK2 A203T

CI-VAR-00000079Explore in graph →CIViC 3147

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Primary Myelofibrosis2
NTRK2 A203T	(oncogenic)	Oncogenic	C	Supports Oncogenicity	3	submitted	EID8619 In this study deep sequencing was performed on 185 patients with hematological malignancies, and the NTRK2 A203T substitution was detected in one case of primary myelofibrosis. The substitution is loc… (full text at CIViC) PMID 32315394 · Joshi et al., 2020 · Open in CIViC	civic
NTRK2 A203T	Entrectinib + LarotrectinibSubstitutes	Predictive	D	Supports Sensitivity Response	3	submitted	EID8620 Deep sequencing of samples from 185 patients with different hematological malignancies detected an NTRK2 A203T substitution in one case of primary myelofibrosis. When stably expressed into murine inte… (full text at CIViC) PMID 32315394 · Joshi et al., 2020 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.